• Tris Pharma Inc., of Monmouth Junction, N.J., and FSC Laboratories Inc., of Charlotte, N.C., signed a license agreement for commercialization of Karbinal ER (carbinoxamine maleate) extended-release oral suspension, a sustained-release histamine receptor blocking agent for allergic rhinitis in children 2 and older.